Flubromazolam’s purpose in clinical trials is limited on account of its classification to be a designer drug. Nevertheless, its results are already reversed via the benzodiazepine antagonist flumazenil in pharmacokinetic scientific studies, delivering insights into its scientific implications and crisis management of overdoses.Have upper body pa

Article Under Review

Article Under Review